10.1016/s1470-2045(09)70284-0 - Lenalidomide plus high-dose dexametha...

This document has been corrected

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

10.1016/s1470-2045(09)70284-0

Published Online: 2010-01-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: David H Vesole•David S Siegel•Michael E Williams•Michael Katz•Natalie S Callander•Philip R Greipp•Rafael Fonseca•Rafat Abonour•S Vincent Rajkumar•Susanna Jacobus

This document has been corrected

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

10.1016/s1470-2045(09)70284-0

Published Online: 2010-01-?

Journal: The Lancet Oncology

Authors: David H Vesole•David S Siegel•Michael E Williams•Michael Katz•Natalie S Callander•Philip R Greipp•Rafael Fonseca•Rafat Abonour•S Vincent Rajkumar•Susanna Jacobus

NOW

2010-01-01•Erratum

Errata

10.1016/s1470-2045(09)70394-8

* information provided by CrossRef

2010-01-01•Erratum

10.1016/s1470-2045(09)70394-8

* information provided by CrossRef

2010-01-?•Published

This document has been corrected

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

10.1016/s1470-2045(09)70284-0

Published Online: 2010-01-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: David H Vesole•David S Siegel•Michael E Williams•Michael Katz•Natalie S Callander•Philip R Greipp•Rafael Fonseca•Rafat Abonour•S Vincent Rajkumar•Susanna Jacobus